Ragini Kudchadkar, MD

Articles

Dr. Kudchadkar on the Durability of Immunotherapy in Non-Melanoma Skin Cancers

November 23rd 2020

Ragini Kudchadkar, MD, discusses the durability of immunotherapy in non-melanoma skin cancers.

Dr. Kudchadkar on Immunotherapy in Merkel Cell Carcinoma

January 10th 2018

Ragini Kudchadkar, MD, assistant professor, Department of Hematology and Medical Oncology, associate director, Hematology and Medical Oncology Fellowship Program-Clinical/Service, Emory University School of Medicine, discusses immunotherapy in Merkel cell carcinoma.

Dr. Kudchadkar on the FDA Approval of Avelumab in Merkel Cell Carcinoma

March 23rd 2017

Ragini Kudchadkar, MD, assistant professor, Department of Hematology and Medical Oncology, associate director, Hematology and Medical Oncology Fellowship Program-Clinical/Service, Emory University School of Medicine, discusses the FDA approval of avelumab for the treatment of patients with Merkel cell carcinoma.

Dr. Kudchadkar on Combining Therapies for Melanoma

November 1st 2013

Ragini Kudchadkar, MD, assistant professor, medical oncology, Moffitt Cancer Center, discusses the potential for combining therapies for the treatment of melanoma.

Dr. Kudchadkar Discusses Melanoma Testing

October 17th 2013

Ragini Kudchadkar, MD, assistant professor, medical oncology, Moffitt Cancer Center, discusses testing for melanoma.

Dr. Kudchadkar on BRAF and MEK Inhibitors in Melanoma

October 4th 2013

Ragini Kudchadkar, MD, assistant professor, medical oncology, Moffitt Cancer Center, discusses the benefits of combining BRAF and MEK inhibitors when treating melanoma.

x